<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1002" relname="background">Cancer has been a major threat to human health in recent years .</segment>
<segment id="3" parent="1003" relname="preparation">In the past forty years ,</segment>
<segment id="4" parent="1004" relname="concession">even though great efforts have been made ,</segment>
<segment id="5" parent="1006" relname="span">there is still much</segment>
<segment id="6" parent="5" relname="elaboration">to be done</segment>
<segment id="7" parent="1006" relname="circumstance">before a safe therapy is achieved .</segment>
<segment id="8" parent="1004" relname="joint">Currently , chemotherapy and radiotherapy are still the main therapeutic methods for cancer .</segment>
<segment id="9" parent="1004" relname="joint">However , most of the anticancer drugs have toxic side effects .</segment>
<segment id="10" parent="1010" relname="span">Therefore , it is critical to develop novel anticancer drugs</segment>
<segment id="11" parent="10" relname="elaboration">that have no toxic side effects on other tissues or organs in vivo ,</segment>
<segment id="12" parent="1012" relname="span">and only target the lesion area .</segment>
<segment id="13" parent="1014" relname="attribution">Compared with traditional chemotherapeutic drugs ,</segment>
<segment id="14" parent="1014" relname="span">the nano-anticancer drug therapy has potential application prospects</segment>
<segment id="15" parent="14" relname="elaboration">in curing cancer diseases .</segment>
<segment id="16" parent="1004" relname="joint">One of the major concerns about the nano-anticancer drugs is the drug-delivery vector .</segment>
<segment id="17" parent="1004" relname="joint">The ideal delivery vector should possess such characteristics as a high drug-loading capacity , low immunogenicity , low toxicity , better shelf-life , and water solubility ,</segment>
<segment id="18" parent="1004" relname="joint">and it should have the potential to be further modified .</segment>
<segment id="19" parent="1020" relname="span">Synthetic polymers , such as , chitosan , polyetherimide</segment>
<segment id="20" parent="1021" relname="span">( PEI ) ,</segment>
<segment id="21" parent="1022" relname="span">poly(lactic-co-glycolic acid )</segment>
<segment id="22" parent="21" relname="restatement">( PLGA ) ,</segment>
<segment id="23" parent="1025" relname="span">polyamidoamine</segment>
<segment id="24" parent="23" relname="elaboration">( PAMAM ) , and poly-l-lactic acid</segment>
<segment id="25" parent="1025" relname="elaboration">( PLA )</segment>
<segment id="26" parent="1023" relname="same_unit">have been widely used in gene- and drug-delivery systems .</segment>
<segment id="27" parent="1028" relname="span">However , stability of sustained-release formulations in aqueous solution , long delivery times , and low delivery efficiency are only a small part of the challenges</segment>
<segment id="28" parent="27" relname="elaboration">highlighted by researchers .</segment>
<segment id="29" parent="1031" relname="span">Dendrigraft poly-l-lysines</segment>
<segment id="30" parent="29" relname="elaboration">( DGL )</segment>
<segment id="31" parent="1032" relname="span">have emerged as a new kind of synthetic polymer</segment>
<segment id="32" parent="1033" relname="joint">consisting of lysine</segment>
<segment id="33" parent="1035" relname="circumstance">and have been employed as drug- or gene-delivery carriers ,</segment>
<segment id="34" parent="1035" relname="span">due to their biodegradability and rich external amino groups</segment>
<segment id="35" parent="34" relname="elaboration">that can encapsulate drugs by the emulsion crosslinking method or plasmid DNA through electric interactions .</segment>
<segment id="36" parent="1036" relname="span">Besides their biodegradability ,</segment>
<segment id="37" parent="1038" relname="span">they can also be modified with targeting ligands and polyethylene glycol</segment>
<segment id="38" parent="37" relname="elaboration">( PEG ) ,</segment>
<segment id="39" parent="1037" relname="same_unit">thereby rendering vectors with targeting properties and long circulation .</segment>
<segment id="40" parent="1040" relname="span">As yet , there are only a few ways</segment>
<segment id="41" parent="40" relname="elaboration">available for targeted delivery of anticancer drugs .</segment>
<segment id="42" parent="1043" relname="attribution">Recently , a report showed</segment>
<segment id="43" parent="1044" relname="span">that VAR2CSA ,</segment>
<segment id="44" parent="1045" relname="span">which is exposed on the membrane of Plasmodium falciparum infected red blood cells</segment>
<segment id="45" parent="44" relname="elaboration">( iRBC ) ,</segment>
<segment id="46" parent="1046" relname="span">could bind to 90 % of tumors ,</segment>
<segment id="47" parent="1047" relname="span">which was verified</segment>
<segment id="48" parent="47" relname="means">by running immunohistochemistry on a tumor-tissue array .</segment>
<segment id="49" parent="1004" relname="joint">Therefore , VAR2CSA is becoming an attractive target for anticancer drugs â€™ development .</segment>
<segment id="50" parent="1051" relname="span">P. falciparum infection during pregnancy results in the sequestration of iRBC in the placenta</segment>
<segment id="51" parent="1053" relname="span">by adhering to a distinct type of chondroitin sulfate A</segment>
<segment id="52" parent="51" relname="restatement">( CSA )</segment>
<segment id="53" parent="1052" relname="same_unit">exclusively expressed on trophoblast via VAR2CSA .</segment>
<segment id="54" parent="1004" relname="joint">Short continuous regions of VAR2CSA with affinity for multiple types of CSA were defined .</segment>
<segment id="55" parent="1056" relname="span">A 28 amino acids placenta CSA-binding peptide</segment>
<segment id="56" parent="55" relname="restatement">( plCSA-BP )</segment>
<segment id="57" parent="1057" relname="same_unit">from the VAR2CSA region</segment>
<segment id="58" parent="1057" relname="same_unit">was recently tested as a guide peptide for targeted delivery of doxorubicin to choriocarcinoma .</segment>
<segment id="59" parent="1059" relname="span">However , whether it could be used</segment>
<segment id="60" parent="1060" relname="span">to modify the DGL and its bioactivity</segment>
<segment id="61" parent="1061" relname="same_unit">after the modification</segment>
<segment id="62" parent="1061" relname="same_unit">was not evaluated .</segment>
<segment id="63" parent="1058" relname="joint">The immunosuppressive , antimalarial , and pro-cytotoxic bacterial prodigiosin was recently described as a potent antimetastatic and anticancer agent .</segment>
<segment id="64" parent="1058" relname="joint">It can induce apoptosis in a wide range of cancer cell lines , including hematopoietic cancer , breast cancer , gastric cancer , colon cancer , lung cancer , and rat hepatocellular carcinoma cell lines ,</segment>
<segment id="65" parent="1065" relname="preparation">with no marked toxicity in nonmalignant cells .</segment>
<segment id="66" parent="1065" relname="joint">However , prodigiosin has not been reported for the treatment of choriocarcinoma yet .</segment>
<segment id="67" parent="1067" relname="span">It is selective in promoting apoptosis of malignant tumor cells ,</segment>
<segment id="68" parent="67" relname="elaboration">rendering prodigiosin a promising anticancer agent .</segment>
<segment id="69" parent="1069" relname="span">The antitumor mechanism of prodigiosin is still unclear ,</segment>
<segment id="70" parent="1070" relname="span">especially in regard to newly acquired prodigiosin</segment>
<segment id="71" parent="1071" relname="span">produced by a small number of microorganisms ,</segment>
<segment id="72" parent="71" relname="elaboration">including Serratia marcescens and other bacteria , such as Streptomyces griseoviridis , Serratia spp. , Zooshikellarubidus , Vibrio sp . , Actinomycetes , and Hahella chejuensis .</segment>
<segment id="73" parent="1073" relname="span">Research on the mechanism of bacterial origin prodigiosin is very important for clinical application and drug development .</segment>
<segment id="74" parent="1075" relname="span">In this study ,</segment>
<segment id="75" parent="1076" relname="joint">to develop a new type of targeted drug delivery carrier material</segment>
<segment id="76" parent="1077" relname="span">and investigate the anticancer mechanism of prodigiosin , we first used plCSA-BP as a guide peptide</segment>
<segment id="77" parent="1078" relname="span">to coat on the DGL vector for cancer-cell-targeted delivery of prodigiosin</segment>
<segment id="78" parent="77" relname="elaboration">produced from Serratia marcescens subsp . lawsoniana HDZK-BYSB107 .</segment>
<segment id="79" parent="1079" relname="joint">Then , we tested the binding ability of the newly developed DGL/CSA-PNPs and its anticancer effect in vitro on a JEG3 choriocarcinoma cell line and in vivo on a tumor model , respectively .</segment>
<segment id="80" parent="1080" relname="span">In addition , the mechanism</segment>
<segment id="81" parent="80" relname="elaboration">responsible for the anticancer effect of targeted nano-prodigiosin was also investigated .</segment>
<segment id="82" parent="1082" relname="attribution">Overall , these findings suggested</segment>
<segment id="83" parent="1082" relname="span">that the DGL/CSA vector is an excellent cancer-specific-drug delivery carrier ,</segment>
<segment id="84" parent="83" relname="elaboration">which has great potential as a novel delivery system for the treatment of cancer .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1004" type="multinuc" parent="1003" relname="span"/>
<group id="1005" type="span" parent="1004" relname="joint"/>
<group id="1006" type="span" parent="1005" relname="span"/>
<group id="1010" type="span" parent="1004" relname="joint"/>
<group id="1012" type="span" parent="1004" relname="joint"/>
<group id="1013" type="span" parent="12" relname="elaboration"/>
<group id="1014" type="span" parent="1013" relname="span"/>
<group id="1020" type="span" parent="1004" relname="joint"/>
<group id="1021" type="span" parent="19" relname="elaboration"/>
<group id="1022" type="span" parent="20" relname="restatement"/>
<group id="1023" type="multinuc" parent="1004" relname="joint"/>
<group id="1024" type="span" parent="1023" relname="same_unit"/>
<group id="1025" type="span" parent="1024" relname="span"/>
<group id="1027" type="span" parent="1004" relname="joint"/>
<group id="1028" type="span" parent="1027" relname="span"/>
<group id="1029" type="span" parent="1028" relname="elaboration"/>
<group id="1030" type="multinuc" parent="1029" relname="span"/>
<group id="1031" type="span" parent="1030" relname="same_unit"/>
<group id="1032" type="span" parent="1030" relname="same_unit"/>
<group id="1033" type="multinuc" parent="31" relname="elaboration"/>
<group id="1034" type="span" parent="1033" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="span"/>
<group id="1036" type="span" parent="1030" relname="elaboration"/>
<group id="1037" type="multinuc" parent="36" relname="elaboration"/>
<group id="1038" type="span" parent="1037" relname="same_unit"/>
<group id="1040" type="span" parent="1004" relname="joint"/>
<group id="1042" type="span" parent="1004" relname="joint"/>
<group id="1043" type="multinuc" parent="1042" relname="span"/>
<group id="1044" type="span" parent="1043" relname="same_unit"/>
<group id="1045" type="span" parent="43" relname="elaboration"/>
<group id="1046" type="span" parent="1043" relname="same_unit"/>
<group id="1047" type="span" parent="46" relname="elaboration"/>
<group id="1051" type="span" parent="1004" relname="joint"/>
<group id="1052" type="multinuc" parent="50" relname="means"/>
<group id="1053" type="span" parent="1052" relname="same_unit"/>
<group id="1054" type="multinuc" parent="1004" relname="joint"/>
<group id="1055" type="multinuc" parent="1054" relname="contrast"/>
<group id="1056" type="span" parent="1055" relname="same_unit"/>
<group id="1057" type="multinuc" parent="1055" relname="same_unit"/>
<group id="1058" type="multinuc" parent="1054" relname="contrast"/>
<group id="1059" type="span" parent="1058" relname="joint"/>
<group id="1060" type="span" parent="59" relname="purpose"/>
<group id="1061" type="multinuc" parent="60" relname="circumstance"/>
<group id="1064" type="span" parent="1058" relname="joint"/>
<group id="1065" type="multinuc" parent="1064" relname="span"/>
<group id="1067" type="span" parent="1065" relname="joint"/>
<group id="1069" type="span" parent="1065" relname="joint"/>
<group id="1070" type="span" parent="69" relname="elaboration"/>
<group id="1071" type="span" parent="70" relname="elaboration"/>
<group id="1073" type="span" parent="1065" relname="joint"/>
<group id="1074" type="multinuc" parent="73" relname="elaboration"/>
<group id="1075" type="span" parent="1074" relname="joint"/>
<group id="1076" type="multinuc" parent="74" relname="purpose"/>
<group id="1077" type="span" parent="1076" relname="joint"/>
<group id="1078" type="span" parent="76" relname="purpose"/>
<group id="1079" type="multinuc" parent="1074" relname="joint"/>
<group id="1080" type="span" parent="1079" relname="joint"/>
<group id="1081" type="span" parent="1065" relname="joint"/>
<group id="1082" type="span" parent="1081" relname="span"/>
	</body>
</rst>
